Get the Stockscreener App
9.20
3.06%
-0.29
Regenxbio Inc stock is traded at $9.20, with a volume of 291.08K.
It is down -3.06% in the last 24 hours and up +13.58% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$9.49
Open:
$9.47
24h Volume:
291.08K
Relative Volume:
0.43
Market Cap:
$464.73M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.749
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-5.25%
1M Performance:
+13.58%
6M Performance:
+37.93%
1Y Performance:
-24.47%
1-Day Range:
$9.10
$9.6115
1-Week Range:
$9.10
$10.08
52-Week Range:
$5.035
$13.48
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
9.20 | 483.42M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
REGENXBIO (NASDAQ:RGNX) Given "Buy" Rating at Chardan Capital - MarketBeat
Insider Sell: Curran Simpson Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Ultragenyx Makes Bid for Dimension TherapeuticsBiotech Movers - TheStreet
Ieq Capital LLC Takes Position in REGENXBIO Inc. $RGNX - MarketBeat
Invesco Ltd. Purchases 27,341 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Exome Asset Management LLC Purchases New Position in REGENXBIO Inc. $RGNX - MarketBeat
Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year - CGTLive®
HC Wainwright Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Can REGENXBIO Inc. maintain sales growthInsider Buying & Fast Exit Strategy with Risk Control - Lancaster City Council
Is REGENXBIO Inc. in a long term uptrendTrade Volume Summary & AI Forecast Swing Trade Picks - Lancaster City Council
Regenxbio says FDA extends review date for Hunter syndrome drug - MSN
Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome - Seeking Alpha
PDT Partners LLC Buys 39,501 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Regenxbio at Morgan Stanley Conference: Gene Therapy Progress and Financial Strength - Investing.com Canada
Moving Average Crossover Confirms Uptrend in REGENXBIO Inc.July 2025 Summary & Weekly High Conviction Ideas - beatles.ru
Regenxbio stock rating reiterated at Buy by H.C. Wainwright on positive trial data - Investing.com
Pattern Scan Adds REGENXBIO Inc. to WatchlistJuly 2025 Chart Watch & Fast Gaining Stock Strategy Reports - beatles.ru
Trade Report: What is REGENXBIO Inc. s debt to equity ratio2025 Top Gainers & Weekly High Return Forecasts - 뉴스영
124,700 Shares in REGENXBIO Inc. $RGNX Bought by Nuveen LLC - MarketBeat
Trexquant Investment LP Buys 308,516 Shares of REGENXBIO Inc. $RGNX - MarketBeat
ADAR1 Capital Management LLC Acquires 162,423 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Hsbc Holdings PLC Has $390,000 Holdings in REGENXBIO Inc. $RGNX - MarketBeat
RegenXBio (RGNX) Receives a Buy from Raymond James - The Globe and Mail
What recovery options are there for REGENXBIO Inc.2025 Risk Factors & Expert Approved Momentum Ideas - Newser
REGENXBIO Inc. recovery potential after sell offAnalyst Downgrade & Safe Entry Zone Identification - Newser
Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX) - Seeking Alpha
Can REGENXBIO Inc. expand into new markets2025 Earnings Surprises & Advanced Technical Signal Analysis - خودرو بانک
Top chart patterns to watch in REGENXBIO Inc.Weekly Investment Recap & AI Optimized Trading Strategy Guides - Newser
Is REGENXBIO Inc.’s ROIC above industry averageTreasury Yields & Real-Time Stock Movement Alerts - خودرو بانک
Goldman Sachs reiterates Neutral rating on Regenxbio stock at $14 target - Investing.com Australia
REGENXBIO reports positive one-year data for MPS II gene therapy - Investing.com Nigeria
Should value investors consider REGENXBIO Inc.2025 Stock Rankings & Daily Stock Trend Reports - خودرو بانک
Goldman Sachs reiterates Neutral rating on Regenxbio stock at $14 target By Investing.com - Investing.com South Africa
Can REGENXBIO Inc. expand its profit marginsWeekly Risk Report & Free Reliable Trade Execution Plans - خودرو بانک
Regenxbio stock maintains Outperform rating at Raymond James on MPS II data - Investing.com Nigeria
Regenxbio stock maintains Outperform rating at Raymond James on MPS II data By Investing.com - Investing.com South Africa
Will REGENXBIO Inc. bounce back from current supportQuarterly Profit Summary & Safe Investment Capital Preservation Plans - Newser
Risk adjusted return profile for REGENXBIO Inc. analyzed2025 Price Targets & Low Risk Entry Point Tips - Newser
REGENXBIO reports positive one-year data for MPS II gene therapy By Investing.com - Investing.com South Africa
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date - Yahoo Finance
Long term hold vs stop loss in REGENXBIO Inc.Fed Meeting & Daily Oversold Bounce Ideas - Newser
Regenxbio trumpets one-year data for Hunter syndrome gene therapy after FDA extended its review - Endpoints News
REGENXBIO reports positive data from Hunter syndrome (RGNX) - Seeking Alpha
Navigating Biotech Innovation Amid Sector Volatility: High-Conviction Opportunities in 2025 - AInvest
Sector Update: Health Care Stocks Mixed Pre-Bell Friday - MarketScreener
RGX-121 and the Path to Accelerated FDA Approval: A Strategic Inflection Point for REGENXBIO - AInvest
Can machine learning forecast REGENXBIO Inc. recoveryWeekly Trend Summary & Consistent Growth Equity Picks - Newser
82% Brain Disease Marker Drop: REGENXBIO's One-Time Hunter Syndrome Treatment Shows Promise in Pivotal Trial - Stock Titan
What MACD signals say about REGENXBIO Inc.Trend Reversal & Free Safe Capital Growth Stock Tips - Newser
Should you wait for a breakout in REGENXBIO Inc.2025 Fundamental Recap & High Accuracy Investment Signals - Newser
Jump Financial LLC Sells 85,354 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):